Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Double-cohort, Multicenter, Phase II Study of Gemcitabine and Albumin Paclitaxel in Combination With PD-L1 Antibodies Followed by Liposomal Irinotecan Combined With Oxaliplatin, 5-FU/LV and PD-L1 Antibodies as Conversion Therapy for Borderline Resectable/Local Advanced Pancreatic Cancer

NCT07208539 is registered in ClinicalTrials.gov with Shanghai Zhongshan Hospital as lead sponsor.

NCT NCT07208539
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07208539 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Double-cohort, Multicenter, Phase II Study of Gemcitabine and Albumin Paclitaxel in Combination With PD-L1 Antibodies Followed by Liposomal Irinotecan Combined With Oxaliplatin, 5-FU/LV and PD-L1 Antibodies as Conversion Therapy for Borderline Resectable/Local Advanced Pancreatic Cancer
Lead sponsor
Shanghai Zhongshan Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 10, 2025
Completion date
December 31, 2026
Enrollment
77 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer